



(11) **EP 4 428 157 A3**

(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:
11.12.2024 Bulletin 2024/50

(43) Date of publication A2:
11.09.2024 Bulletin 2024/37

(21) Application number: **24189348.6**

(22) Date of filing: **02.08.2018**

(51) International Patent Classification (IPC):
C12Q 1/6886 ^(2018.01) **G01N 33/574** ^(2006.01)
A61K 45/06 ^(2006.01) **A61K 39/395** ^(2006.01)
C07K 16/28 ^(2006.01)

(52) Cooperative Patent Classification (CPC):
C12Q 1/6886; G16H 20/40; G16H 50/20;
G16H 50/30; C12Q 2600/106; C12Q 2600/118;
C12Q 2600/158; Y02A 90/10

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **04.08.2017 US 201762541566 P**

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
18841393.4 / 3 662 082

(71) Applicants:
• **Veracyte SD, Inc.**
San Diego, CA 92121 (US)
• **The Regents Of The University Of Michigan**
Ann Arbor, Michigan 48109-1280 (US)

(72) Inventors:
• **DAVICIONI, Elai**
La Jolla, 92037 (US)
• **ERHO, Nicholas George**
Vancouver, V6B 6H4 (CA)
• **LEHRER, Jonathan**
Vancouver, V5L 4H2 (CA)
• **FENG, Felix Y**
Hillsborough, 94010 (US)
• **ZHAO, Shuang G**
Ann Arbor, 48105 (US)

(74) Representative: **Cabinet Becker et Associés**
25, rue Louis le Grand
75002 Paris (FR)

(54) **USE OF IMMUNE CELL-SPECIFIC GENE EXPRESSION FOR PROGNOSIS OF PROSTATE
CANCER AND PREDICTION OF RESPONSIVENESS TO RADIATION THERAPY**

(57) Methods, systems, and kits for the diagnosis,
prognosis and the determination of cancer progression
of prostate cancer in a subject are disclosed. In particular,
the disclosure relates to the use of immune cell-specific

gene expression in determining prognosis and identifying
individuals in need of treatment for prostate cancer who
will be responsive to radiation therapy.

EP 4 428 157 A3



EUROPEAN SEARCH REPORT

Application Number

EP 24 18 9348

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	DEN ROBERT B ET AL: "Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy", INTERNATIONAL JOURNAL OF RADIATION: ONCOLOGY BIOLOGY PHYSICS, PERGAMON PRESS, USA, vol. 89, no. 5, 8 July 2014 (2014-07-08), pages 1038-1046, XP028864005, ISSN: 0360-3016, DOI: 10.1016/J.IJROBP.2014.04.052 * Abstract; Introduction, column 2; Figures 1-2; Discussion *	1-6	INV. C12Q1/6886 G01N33/574 A61K45/06 A61K39/395 C07K16/28
A	ZHAO SHUANG G ET AL: "Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis", THE LANCET ONCOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 17, no. 11, 12 October 2016 (2016-10-12), pages 1612-1620, XP029794201, DOI: 10.1016/S1470-2045(16)30491-0 * Abstract; page 1615, panel; Discussion *	1-6	TECHNICAL FIELDS SEARCHED (IPC) C12Q G01N
A	JENNIFER H. YEARLEY ET AL: "PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer", CLINICAL CANCER RESEARCH, vol. 23, no. 12, 15 June 2017 (2017-06-15), pages 3158-3167, XP055487022, US ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-16-1761 * Abstract; Figure 4 *	1-6	
The present search report has been drawn up for all claims			

2

EPO FORM 1503 03:82 (P04C01)

Place of search	Date of completion of the search	Examiner
The Hague	31 October 2024	Aguilera, Miguel
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document		